Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Radioactive agent approved for adrenal tumors

FDA approves iobenguane I 131 injection (Azedra) for IV use for the treatment of pheochromocytoma or paraganglioma. 

Key clinical point: The FDA has approved iobenguane I 131 injection (Azedra) for intravenous use for the treatment of adults and adolescents aged 12 years and older with rare adrenal tumors (pheochromocytoma or paraganglioma) that are unresectable, have metastasized, and require systemic therapy.

Major finding: The primary endpoint was the number of patients with a 50% or greater reduction of antihypertensive medications lasting at least 6 months; the secondary endpoint was overall tumor response according to traditional imaging criteria. Among 68 patients, the primary endpoint was met by 17, and the secondary endpoint was achieved in 15.

Study details: Approval is based on a single-arm, open-label clinical trial that included 68 patients.

Disclosures: The FDA granted the approval of Azedra to Progenics Pharmaceuticals.


FDA approves iobenguane I 131 injection (Azedra) for IV use for pheochromocytoma or paraganglioma.

This Week's Must Reads

Inadequate emergency care a challenge for rural pediatric patients, Walling EB et al. J Oncol Pract. 2019 Jan 31. doi: 10.1200/JOP.18.00115.

QC measures improve with CMS Oncology Care Model, Rocque G et al. J Oncol Pract. 2019. doi: 10. 1200/JOP.18.00390.

Women less likely to receive industry funds, Weng JK et al. JAMA Netw Open. 2019 Jan. 25. doi: 10.1001/jamanetworkopen.2018.7377.

A shift in Medicare drug coverage may boost costs for patients, Hwang TJ et al. JAMA Int Med. 2019. doi: 10.1001/jamainternmed.2018.6417.

President Trump requests $500 million for pediatric cancer, Trump D. State of the Union Address, Feb. 5, 2019.

Must Reads in Genitourinary Cancer

Obesity-related cancers such as kidney cancer rising among young adults, Sung H et al. Lancet Public Health. 2019 Feb 4.

Leptin expression may aid in differentiation of renal lesions, Gobe G et al. Pathology. 2018 Aug;50(5):504-10

Hypofractionated radiation offers 'tailored treatment' approach to RCC mets, Felice F et al. Crit Rev Oncol Hematol. 2018 Aug 1. doi: 10.1016/j.critrevonc.2018.06.002.

Concern over SREs rises with increasing incidence of metastatic RCC, Umer M et al. Ann Med Surg. 2018 Jan 21. doi: 10.1016/j.amsu.2018.01.002